Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 690 participants.

Also called NCT01560624

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 690 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01560624
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01560624. Randomized; quadruple masking; primary purpose treatment. Start 2012-06-26 (actual); primary completion 2018-06-24 (actual). Results posted on 2020-02-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
Acronym
FREEDOM-EV
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Treprostinil Diolamine
Intervention (Drug)
Placebo
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01560624
Content hash
b63256ed1d7e3ec9663d987d3a9943028604a4e6dd423509ac2717014bee6755